Sort By:

News From the PET Front: Early Amyloid Networks and Tau Mystery

CONFERENCE COVERAGE 2018-04-10 Conference Coverage The advent of PET to image Alzheimer’s pathology in people has handed researchers new tools for staging disease during life, but PET also presents mysteries. At the first Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting ...

CTAD Lessons for 2020: More Phase 2 Trials, More Diversity

CONFERENCE COVERAGE 2020-01-09 Conference Coverage What lies ahead for Alzheimer’s therapy development? While anti-amyloid antibodies are at last signaling some success, researchers agree that these expensive—and, thus far, at best modestly effective—biologic drugs can form only part ...

Fluid AD Biomarkers Link P-Tau to Synapses, Inflammation

CONFERENCE COVERAGE 2019-12-19 Conference Coverage CSF Aβ42 and phospho-tau may remain the quintessential fluid Alzheimer’s disease biomarkers for now, but a growing cadre of other markers are also proving their worth. At the Clinical Trials on Alzheimer’s Disease conference, held ...

2018—A Year in Research

RESEARCH NEWS 2018-12-28 Research News Once again, it’s time to reflect on the preceding 12 months. Despite the 2025 deadline for effective therapy that has been set by the National Alzheimer’s Plan and the World Dementia Council, 2018 brought no drug approvals or Phase 3 ...

Could New Glutamate Receptor Activators Treat Alzheimer’s?

RESEARCH NEWS 2020-01-16 Research News According to an article in the January 14 Cell Reports, boosting the activity of certain excitatory receptors in the brain calms epileptic activity and improves learning and memory in mouse models of disease. Jesse Hanson, Genentech Inc. in ...

Tangle Density Foretells How Fast a Person’s Brain Will Shrink

RESEARCH NEWS 2020-01-10 Research News A new study supports the idea that deposits of tau predict that a person’s brain will soon wither. Investigators led by Renaud La Joie and Gil Rabinovici, University of California, San Francisco, found that in people with mild Alzheimer’s ...

Brain Conference Spotlights Transcriptomics, Therapeutic Strategies

CONFERENCE COVERAGE 2019-05-24 Conference Coverage About 140 scientists gathered in Rungstedgaard, north of Copenhagen, Denmark, May 5–9 for the biannual Brain Conference organized by the Federation of European Neuroscience Societies and the Lundbeck Foundation. Co-chaired by Beth ...

Paper Alert: Lipid Droplet-Filled Microglia Harm the Brain

RESEARCH NEWS 2020-01-21 Research News In the January 20 Nature Neuroscience, researchers led by Tony Wyss-Coray at Stanford University, Palo Alto, California, identify a microglial subtype that accumulates cytoplasmic lipid droplets. These fatty microglia show up in the aging ...

In AD, Chaperones Congregate To Form a Therapeutic Target

RESEARCH NEWS 2020-01-30 Research News A new study reveals a sticky web of protein-protein interactions, centered on heat shock protein 90 (HSP90) and other chaperones, in the brains of people with AD. This network, not found in healthy tissue, appears to entangle a host of ...

Soccer Heading Has Greater Impact on Memory in ApoE4 Carriers

RESEARCH NEWS 2020-01-31 Research News Soccer players who repeatedly bonk their noggins against the ball have losses in episodic memory. The losses are subtle and likely unnoticeable. This subclinical effect is strongest in ApoE4 carriers, according to a study published January ...

Does Young-Onset Parkinson’s Arise in Lysosomes?

RESEARCH NEWS 2020-01-31 Research News One in 10 people with Parkinson’s start noticing signs of the disease between the ages of 20 and 50. Most have no family history, and few carry known autosomal-dominant PD mutations. Can induced pluripotent stem cell (iPSC) modeling help ...

Tau PET Scans Turn Positive When Amyloid Does; Symptoms Follow

CONFERENCE COVERAGE 2020-01-09 Conference Coverage This article was amended on January 10, 2020 Tau PET is prying open a window on when and where neurofibrillary tangles appear as Alzheimer’s progresses. At the 12th Clinical Trials on Alzheimer’s Disease Conference, held December 4–7 ...

Anti-Agitation Drug Comes Up Short in Phase 3

RESEARCH NEWS 2019-10-03 Research News A drug being tested for its ability to calm agitation in Alzheimer’s disease provided no benefit in the TRIAD-1 Phase 3 trial, according to topline results announced by Avanir Pharmaceuticals on September 27 (see press release). The drug, ...

Proteomics Uncovers Potential Markers, Subtypes of Alzheimer’s

CONFERENCE COVERAGE 2019-08-22 Conference Coverage In the last three decades, scientists have made strides in using biomarkers to diagnose Alzheimer’s disease and track its progression. Along with cerebrospinal fluid Aβ, tau, and phospho-tau, a handful of new markers, such as ...

Rare Luck: Two Copies of ApoE2 Shield Against Alzheimer’s

CONFERENCE COVERAGE 2019-08-08 Conference Coverage Mention ApoE and Alzheimer’s, and the conversation turns to the E4 allele, the strongest susceptibility gene for the disease. But ApoE has another side, in ApoE2. Though this isoform protects against AD, scientists have barely studied ...

Current Filters

  • TYPE: News x

Remove all filters

Filter By

  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From